EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System

Hai-Yu Liu, Mei-Yu Qu, Shu-Yun Wang, Jun-Jin Liu, Si-Yang Wang, Rui-Gang Hou

International Journal of Clinical Pharmacy · 28.04.2026 · 48 (4) · 1703-1713

DOI: 10.1007/s11096-026-02153-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 28.04.2026. Verfasst von Hai-Yu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The second Hospital of Shanxi Medical University, Shanxi, 030000, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Disseminated Intravascular Coagulation, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanxi Province, State Key Laboratory of Neurology and Oncology Drug Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsProduct Surveillance, PostmarketingDisseminated Intravascular CoagulationAntineoplastic AgentsProtein Kinase InhibitorsHumansErbB ReceptorsUnited StatesUnited States Food and Drug AdministrationPharmacovigilanceFemaleMaleAgedMiddle Aged

Stichwörter der Autor:innen

Disproportionality analysisDisseminated intravascular coagulationEpidermal growth factor receptor inhibitorsFDA adverse event reporting systemPharmacovigilance

Substanzen

ErbB ReceptorsAntineoplastic AgentsEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • The second Hospital of Shanxi Medical University, Shanxi, 030000, China.
  • School of Pharmacy, Shanxi Medical University, Shanxi, 030000, China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
  • The second Hospital of Shanxi Medical University, Shanxi, 030000, China. ruiganghou9966@163.com.
  • School of Pharmacy, Shanxi Medical University, Shanxi, 030000, China. ruiganghou9966@163.com.
  • Medical Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, 030000, China. ruiganghou9966@163.com.

Förderung

  • Natural Science Foundation of Shanxi Province
  • State Key Laboratory of Neurology and Oncology Drug Development

Zitieren

APA

Liu, H. Y., Qu, M. Y., Wang, S. Y., Liu, J. J., Wang, S. Y., & Hou, R. G. (2026). Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System. International Journal of Clinical Pharmacy, 48(4), 1703-1713. https://doi.org/10.1007/s11096-026-02153-9

Vancouver

Liu HY, Qu MY, Wang SY, Liu JJ, Wang SY, Hou RG. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System. International Journal of Clinical Pharmacy. 2026;48(4):1703-1713. doi:10.1007/s11096-026-02153-9

BibTeX
@article{Liu2026,
  author = {Liu, Hai-Yu and Qu, Mei-Yu and Wang, Shu-Yun and Liu, Jun-Jin and Wang, Si-Yang and Hou, Rui-Gang},
  title = {Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System},
  journal = {International Journal of Clinical Pharmacy},
  year = {2026},
  volume = {48},
  number = {4},
  pages = {1703--1713},
  doi = {10.1007/s11096-026-02153-9}
}
Kostenlos starten →